Reviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH) Stock Price
RVPHStock
$0.47−96.00%52W
Market Cap$6.23M
P/E—
PEG Ratio—
Div yield—
Beta0.61
RVPH Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-54.97%
Price vs S&P 500 (4W)-4.57%
VGM Score34.82
RVPH Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.41 | -$0.19 | +53.66%(+$0.22) | |
| Q1 2026 | -$0.29 | -$0.46 | -58.62%(-$0.17) | |
| Q4 2025 | -$1.07 | -$5.19 | -386.56%(-$4.12) | |
| Q3 2025 | -$1.94 | -$1.20 | +38.24%(+$0.74) | |
| Q2 2025 | -$2.20 | -$2.40 | -9.09%(-$0.20) |
RVPH Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.08
4.08
4.00
4.00
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RVPHReviva Pharmaceuticals Holdings, Inc. Common Stock | — | — | D | — | — | — | — | $0.47 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Reviva Pharmaceuticals Holdings, Inc. Common Stock
Reviva Pharmaceuticals is a late-stage biopharmaceutical company developing therapeutics for central nervous system, inflammatory, and cardiometabolic diseases. Its lead candidate, Brilaroxazine (RP5063), targets multiple neuropsychiatric indications including schizophrenia, bipolar disorder, depression, ADHD, and dementia-related psychosis, with RP1208 also in development. The company uses a chemical genomics-driven platform and proprietary chemistry to discover and develop new medicines.